Denali Therapeutics Inc. (NASDAQ:DNLI) traded at $62.35 at last check on Friday, Nov 20, making an upward move of 0.97% on its previous day’s price.
Looking at the stock we see that its previous close was $61.75 and the beta (5Y monthly) reads 0 with the day’s price range being $60.89 – 62.66. The company has a 12-month trailing PE ratio of 0. In terms of its 52-week price range, DNLI has a high of $72 and a low of $12.39. The company’s stock has gained about 52.37% over that past 30 days.
Denali has a market cap of $8.02 Billion and is expected to release its quarterly earnings report on November 05, 2020. With its Forward Dividend at 0 and a yield of 0%, the company’s investors could be worried for the DNLI stock to lose ahead of the earnings release. Estimates by analysts give the company expected earnings per share (EPS) of $0, with the EPS growth for the year raised at -$1.58 for 2020 and -$1.96 for next year. These figures represent -0.24% and at 0.24% growth in EPS for the two years respectively.
There have been 1 upward and no downward revisions for the stock’s EPS in last 7 days, something that reflects the nature of company’s price movement in short term. On the other hand, looking at the outlook for the DNLI stock, short term indicators assign the stock an average of 100% Buy, while medium term indicators assign it an average of 100% Buy. Long term indicators on average place the stock in the category of 100% Buy.
Let’s briefly compare Denali (DNLI) stock to its peers. We find that today’s price change of +0.97% and +267.2% over the past 12 months for DNLI betters that of Bristol-Myers Squibb Company (BMY), which has seen its stock price fall -0.77% in the latest trading session and is +8.37% over the last one year. Another of its peers Amgen Inc (AMGN) has dropped -0.67% today, but is -2.04% down over the past year, while Gilead Sciences Inc (GILD) is also up 0.97% yet its price remains in the green at 267.2% over the same period. Bristol-Myers has a P/E ratio of 0 compared to Denali’s 0 and Amgen’s 17.99. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial are today at -0.68% and -0.75%, respectively, in early deals.
Coming back to Denali Therapeutics Inc. (NASDAQ:DNLI), we note that the average 3-month trading volume was 648.15 Million, while that of the preceding 10-day period stands at 1.15 Million. Current shares outstanding are 119.29 Million.
According to data from Thomson Reuters, insiders hold 17.61% of the company’s shares while institutions hold 78.82%. The data shows that short shares as of October 29, 2020, stood at 9.16 Million at a short ratio of 16.08. This represents a 7.64% Short interest in Shares outstanding on October 29, 2020. Shares short rose in October from the previous month at 9.13 Million. Investors should be excited about this stock as its upside potential is great, with today’s price pushing the stock +257.92% up in year-to-date price movement.